XNAS 04 May, 2026 12:26 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Robert C. Malenka | Director | Sale of securities on an exchange or to another person at price $ 26.90 per share. | 15 Apr 2026 | 8,593 | 316,466 | - | 26.9 | 231,152 | Voting Common Stock |
| Jonathan Gillis | CAAO and PAO | Sale of securities on an exchange or to another person at price $ 26.61 per share. | 15 Apr 2026 | 3,590 | 251,054 | - | 26.6 | 95,530 | Voting Common Stock |
| Christopher A. Kroeger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 27.49 per share. | 15 Apr 2026 | 7,575 | 1,630,564 | - | 27.5 | 208,237 | Voting Common Stock |
| Christopher A. Kroeger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 27.01 per share. | 15 Apr 2026 | 2,477 | 1,638,139 | - | 27.0 | 66,904 | Voting Common Stock |
| Christopher A. Kroeger | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 26.93 per share. | 15 Apr 2026 | 9,135 | 1,640,616 | - | 26.9 | 246,006 | Voting Common Stock |
| James Lillie | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 26.82 per share. | 15 Apr 2026 | 1,730 | 297,940 | - | 26.8 | 46,399 | Voting Common Stock |
| James Lillie | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 27.01 per share. | 15 Apr 2026 | 686 | 297,254 | - | 27.0 | 18,529 | Voting Common Stock |
| James Lillie | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 27.49 per share. | 15 Apr 2026 | 2,097 | 295,157 | - | 27.5 | 57,647 | Voting Common Stock |
| Kristopher L. Hanson | General Counsel | Sale of securities on an exchange or to another person at price $ 27.01 per share. | 15 Apr 2026 | 73 | 190,390 | - | 27.0 | 1,972 | Voting Common Stock |
| Kristopher L. Hanson | General Counsel | Sale of securities on an exchange or to another person at price $ 27.49 per share. | 15 Apr 2026 | 225 | 190,165 | - | 27.5 | 6,185 | Voting Common Stock |
| Kristopher L. Hanson | General Counsel | Sale of securities on an exchange or to another person at price $ 26.80 per share. | 15 Apr 2026 | 1,529 | 190,463 | - | 26.8 | 40,977 | Voting Common Stock |
| Vishwas Setia | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 27.00 per share. | 15 Apr 2026 | 29 | 392,714 | - | 27 | 783 | Voting Common Stock |
| Vishwas Setia | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 27.49 per share. | 15 Apr 2026 | 87 | 392,627 | - | 27.5 | 2,392 | Voting Common Stock |
| Vishwas Setia | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 26.87 per share. | 15 Apr 2026 | 2,806 | 392,743 | - | 26.9 | 75,397 | Voting Common Stock |
| Erin Pennock Foff | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 27.49 per share. | 15 Apr 2026 | 881 | 400,777 | - | 27.5 | 24,219 | Voting Common Stock |
| Erin Pennock Foff | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 27.01 per share. | 15 Apr 2026 | 288 | 401,658 | - | 27.0 | 7,779 | Voting Common Stock |
| Erin Pennock Foff | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 26.84 per share. | 15 Apr 2026 | 2,044 | 401,946 | - | 26.8 | 54,861 | Voting Common Stock |
| Anatol Kreitzer | Chief Discovery Officer | Sale of securities on an exchange or to another person at price $ 26.61 per share. | 15 Apr 2026 | 3,316 | 256,612 | - | 26.6 | 88,239 | Voting Common Stock |
| Robert C. Malenka | Director | Sale of securities on an exchange or to another person at price $ 19.06 per share. | 20 Feb 2026 | 476 | 325,795 | - | 19.1 | 9,073 | Voting Common Stock |
| Robert C. Malenka | Director | Sale of securities on an exchange or to another person at price $ 18.03 per share. | 20 Feb 2026 | 2,195 | 337,059 | - | 18.0 | 39,576 | Voting Common Stock |
| Robert C. Malenka | Director | Sale of securities on an exchange or to another person at price $ 18.15 per share. | 20 Feb 2026 | 736 | 325,059 | - | 18.1 | 13,358 | Voting Common Stock |
| Robert C. Malenka | Director | Sale of securities on an exchange or to another person at price $ 18.39 per share. | 20 Feb 2026 | 10,788 | 326,271 | - | 18.4 | 198,391 | Voting Common Stock |
| George Pavlov | Director | Purchase of securities on an exchange or from another person at price $ 17.48 per share. | 18 Feb 2026 | 10,658 | 10,658 | - | 17.5 | 186,302 | Voting Common Stock |
| George Pavlov | Director | Purchase of securities on an exchange or from another person at price $ 17.57 per share. | 18 Feb 2026 | 4,422 | 15,080 | - | 17.6 | 77,695 | Voting Common Stock |
| George Pavlov | Director | Purchase of securities on an exchange or from another person at price $ 17.86 per share. | 18 Feb 2026 | 9,920 | 25,000 | - | 17.9 | 177,171 | Voting Common Stock |
| Robert C. Malenka | Director | Sale of securities on an exchange or to another person at price $ 18.21 per share. | 13 Feb 2026 | 12,116 | 339,254 | - | 18.2 | 220,632 | Voting Common Stock |
| Robert C. Malenka | Director | Sale of securities on an exchange or to another person at price $ 18.12 per share. | 10 Feb 2026 | 6,622 | 351,611 | - | 18.1 | 119,991 | Voting Common Stock |
| Robert C. Malenka | Director | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 10 Feb 2026 | 241 | 351,370 | - | 18 | 4,338 | Voting Common Stock |
| Timothy John Garnett | Director | Purchase of securities on an exchange or from another person at price $ 17.89 per share. | 10 Feb 2026 | 14,124 | 14,124 | - | 17.9 | 252,678 | Voting Common Stock |
| James Lillie | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2026 | 7,730 | 298,862 | - | 0 | Voting Common Stock | |
| Christopher A. Kroeger | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2026 | 23,145 | 1,649,751 | - | 0 | Voting Common Stock | |
| James Lillie | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2026 | 31,395 | 31,395 | - | - | Employee Stock Option (right to buy) | |
| Kristopher L. Hanson | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2026 | 7,730 | 191,582 | - | 0 | Voting Common Stock | |
| Kristopher L. Hanson | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2026 | 31,395 | 31,395 | - | - | Employee Stock Option (right to buy) | |
| Vishwas Setia | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2026 | 7,730 | 395,549 | - | 0 | Voting Common Stock | |
| Vishwas Setia | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2026 | 31,395 | 31,395 | - | - | Employee Stock Option (right to buy) | |
| Erin Pennock Foff | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2026 | 13,360 | 403,835 | - | 0 | Voting Common Stock | |
| Erin Pennock Foff | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2026 | 54,240 | 54,240 | - | - | Employee Stock Option (right to buy) | |
| Anatol Kreitzer | Chief Discovery Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2026 | 24,455 | 24,455 | - | - | Employee Stock Option (right to buy) | |
| Anatol Kreitzer | Chief Discovery Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2026 | 6,020 | 259,928 | - | 0 | Voting Common Stock | |
| Christopher A. Kroeger | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2026 | 93,955 | 93,955 | - | - | Employee Stock Option (right to buy) | |
| Jonathan Gillis | CAAO and PAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2026 | 24,455 | 24,455 | - | - | Employee Stock Option (right to buy) | |
| Jonathan Gillis | CAAO and PAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2026 | 6,020 | 254,523 | - | 0 | Voting Common Stock | |
| Robert C. Malenka | Director | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 02 Feb 2026 | 1 | 358,233 | - | 18 | 18 | Voting Common Stock |
| Robert C. Malenka | Director | Sale of securities on an exchange or to another person at price $ 18.02 per share. | 02 Feb 2026 | 7,039 | 358,234 | - | 18.0 | 126,843 | Voting Common Stock |
| Robert C. Malenka | Director | Sale of securities on an exchange or to another person at price $ 19.05 per share. | 28 Jan 2026 | 664 | 393,147 | - | 19.0 | 12,649 | Voting Common Stock |
| Robert C. Malenka | Director | Sale of securities on an exchange or to another person at price $ 18.55 per share. | 28 Jan 2026 | 21,262 | 371,885 | - | 18.5 | 394,410 | Voting Common Stock |
| Robert C. Malenka | Director | Sale of securities on an exchange or to another person at price $ 18.11 per share. | 28 Jan 2026 | 6,612 | 365,273 | - | 18.1 | 119,743 | Voting Common Stock |
| Robert C. Malenka | Director | Sale of securities on an exchange or to another person at price $ 18.61 per share. | 28 Jan 2026 | 5,860 | 393,811 | - | 18.6 | 109,055 | Voting Common Stock |
| James Lillie | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.98 per share. | 27 Jan 2026 | 45,055 | 291,132 | - | 18.0 | 810,089 | Voting Common Stock |
| Jonathan Gillis | CAAO and PAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.98 per share. | 27 Jan 2026 | 22,050 | 248,503 | - | 18.0 | 396,459 | Voting Common Stock |
| Christopher A. Kroeger | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.98 per share. | 27 Jan 2026 | 204,146 | 1,626,606 | - | 18.0 | 3,670,545 | Voting Common Stock |
| Kristopher L. Hanson | General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.98 per share. | 27 Jan 2026 | 26,007 | 183,852 | - | 18.0 | 467,606 | Voting Common Stock |
| Vishwas Setia | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.98 per share. | 27 Jan 2026 | 33,382 | 387,819 | - | 18.0 | 600,208 | Voting Common Stock |
| Erin Pennock Foff | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.98 per share. | 27 Jan 2026 | 44,616 | 390,475 | - | 18.0 | 802,196 | Voting Common Stock |
| Anatol Kreitzer | Chief Discovery Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.98 per share. | 27 Jan 2026 | 42,099 | 253,908 | - | 18.0 | 756,940 | Voting Common Stock |
| Jonathan Gillis | CAAO and PAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2025 | 30,565 | 30,565 | - | 0 | Voting Common Stock | |
| Jonathan Gillis | CAAO and PAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2025 | 124,022 | 124,022 | - | - | Employee Stock Option (right to buy) | |
| Christopher A. Kroeger | Director, Chief Executive Officer | 27 Oct 2025 | 3,895 | 229,588 | - | - | Voting Common Stock | ||
| Christopher A. Kroeger | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2025 | 225,693 | 225,693 | - | 0 | Voting Common Stock | |
| Christopher A. Kroeger | Director, Chief Executive Officer | 27 Oct 2025 | 65,477 | 0 | - | - | Series C Preferred Stock | ||
| Christopher A. Kroeger | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2025 | 916,164 | 916,164 | - | - | Employee Stock Option (right to buy) | |
| James Lillie | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2025 | 132,023 | 132,023 | - | - | Employee Stock Option (right to buy) | |
| James Lillie | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2025 | 32,539 | 32,539 | - | 0 | Voting Common Stock | |
| Kristopher L. Hanson | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2025 | 27,098 | 27,098 | - | 0 | Voting Common Stock | |
| Kristopher L. Hanson | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2025 | 110,046 | 110,046 | - | - | Employee Stock Option (right to buy) | |
| Maria C. Walker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2025 | 6,294 | 6,294 | - | 0 | Voting Common Stock | |
| Maria C. Walker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2025 | 25,604 | 25,604 | - | - | Employee Stock Option (right to buy) | |
| Timothy John Garnett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2025 | 25,604 | 25,604 | - | - | Employee Stock Option (right to buy) | |
| Timothy John Garnett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2025 | 6,294 | 6,294 | - | 0 | Voting Common Stock | |
| Vishwas Setia | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2025 | 43,367 | 43,367 | - | 0 | Voting Common Stock | |
| Vishwas Setia | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2025 | 176,031 | 176,031 | - | - | Employee Stock Option (right to buy) | |
| Erin Pennock Foff | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2025 | 196,035 | 196,035 | - | - | Employee Stock Option (right to buy) | |
| Erin Pennock Foff | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2025 | 48,275 | 48,275 | - | 0 | Voting Common Stock | |
| Anatol Kreitzer | Chief Discovery Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2025 | 146,052 | 146,052 | - | - | Employee Stock Option (right to buy) | |
| Anatol Kreitzer | Chief Discovery Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2025 | 35,953 | 35,953 | - | 0 | Voting Common Stock | |
| Robert C. Malenka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2025 | 34,390 | 399,671 | - | 0 | Voting Common Stock | |
| Robert C. Malenka | Director | 27 Oct 2025 | 3,895 | 31,672 | - | - | Voting Common Stock | ||
| Robert C. Malenka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2025 | 139,610 | 139,610 | - | - | Employee Stock Option (right to buy) | |
| Robert C. Malenka | Director | 27 Oct 2025 | 65,477 | 0 | - | - | Series C Preferred Stock |